نتایج جستجو برای: prostate treatment

تعداد نتایج: 1473921  

Solitary fibrous tumor (SFT) of prostate is an unusual type of mesenchymal neoplasm that can elicit a benign or malignant phenotype. It represents a diagnostic challenge as it can simulate poorly differentiated adenocarcinoma and various mesenchymal neoplasms of prostate. We report a case of prostate SFT in a 54-year-old patient, which was clinically misdiagnosed as nodular hyperplasia of prost...

The treatment of prostate cancer patients usually starts with androgen ablation and followed by chemotherapy; however, in some cases the tumor develops resistant phenotype. Combination therapy is currently regarded as a cornerstone in cancer therapy to overcome the drug resistance. Herein, we investigated the combinatory effect of Docetaxel and Trastuzumab with a novel nanomedicine, BCc1. Also,...

H.J. Kim, J.S. Lee, W.C. Kim,

Background: Based on the radiation biology model of prostate cancer, hypofractionated radiotherapy can improve the treatment outcomes without increasing toxicity. Although hypofractionated radiotherapy is implemented over a short period of time, it is more convenient and cheaper compared with conventional fractionated treatment. The aim of this study was to investigate the early toxicity of mod...

Hsu ChY, Joniau S Oyen R Roskams T VanPoppel H

Background: According to the EAU guidelines, a life expectancy of more than 10 years is considered an important factor in the treatment of prostate cancer. The Charlson score is used to predict mortality based on comorbidies.The purpose of this study was to investigate the relationship between age, Charlson score and outcome in patients with cT3a prostate cancer. Materials and Methods: Between ...

Journal: :middle east journal of cancer 0
katsuya narisada sawami, tobata-ku, kitakyushu-shi, fukuoka, japan

0

Gholamreza Pourmand, Abbas Basiri, Mohammad Taghi Akbari, Seyedeh Maryam Seyedolmohadessin, Zahra Nourmohammadi,

Background: Prostate cancer is the second form of cancer among men worldwide. For early cancer detection, we should identify tumors in initial stages before the physical signs become visible. The present study aims to evaluate the diagnostic value of cell-free DNA (cfDNA), its comparison with prostate-specific antigen (PSA) level in prostate cancer screening and also in patients with localized ...

Journal: :nephro-urology monthly 0
kubat iyazaliev national cancer research center, department of urology, tynystanov, street 64-27, kyrgyzstan ; national cancer research center, department of urology, tynystanov, street 64-27, kyrgyzstan michael siegsmund department of urology, university of heliosweg, germany hans leweling 3department of internal medicine, university of heidelberg, germany

بصیری, ساره, عباسی, محمد,

Background and Objective: Prostate cancer is reported to affect approximately 70% of men and is the second leading cause of death in men. An early diagnosis and screening can reduce the associated complications and mortality rate. Case Presentation: A 52-year-old man complaining of a backache for eight months reported to the hospital. The initial examination showed him to be suffering from an ...

Journal: :journal of research in medical sciences 0
zhong lu department of oncology, clinical college of weifang medical university, weifang, china li qi department of oncology, clinical college of weifang medical university, weifang, china xue jun bo department of urology, the people’s hospital of dongying city, china guo dong liu department of urology, the people’s hospital of weifang city, china jun ming wang department of oncology, clinical college of weifang medical university, weifang, china guixin li department of oncology, clinical college of weifang medical university, weifang, china

normal 0 false false false en-us x-none ar-sa background: prostate cancer is one of the most common cancer types both in western and eastern countries, involving mostly elder men. the mechanisms underlying the prostate cancer development remain unclear. prostate-specific antigen (psa) is the only well accepted marker for prostate cancer diagnosis and prognosis. the diagnosis and treatment of pr...

A. H. Jafari, A. R. Nikoofar, B. Mofid, E. Jazayeri Gharehbagh , S. R. Mahdavi,

Background: To correct patient positioning errors (setup errors) during prostate cancer treatment using EPID and fiducial gold markers, to improve the accuracy of the dose delivery in these patients. Materials and Methods: Fifteen patients with localized prostate carcinoma after implantation of fiducial gold markers in their prostate gland underwent the five-field IMRT planning technique. The p...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید